Merus (NASDAQ:MRUS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS) in a report issued on Monday,Benzinga reports. The firm currently has a $85.00 target price on the biotechnology company’s stock.

Other analysts have also recently issued research reports about the stock. UBS Group began coverage on shares of Merus in a research note on Thursday, October 24th. They issued a “buy” rating and a $72.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Wednesday, November 20th. Guggenheim raised their target price on shares of Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Finally, The Goldman Sachs Group initiated coverage on shares of Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. One research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $85.27.

Merus Price Performance

Shares of NASDAQ:MRUS opened at $45.49 on Monday. The stock has a market cap of $3.11 billion, a P/E ratio of -11.52 and a beta of 1.07. The firm has a fifty day moving average price of $49.86 and a 200 day moving average price of $51.85. Merus has a 1-year low of $22.27 and a 1-year high of $61.61.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $11.77 million for the quarter, compared to analyst estimates of $9.11 million. Sell-side analysts expect that Merus will post -3.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Merus

Several hedge funds have recently modified their holdings of the company. nVerses Capital LLC boosted its position in shares of Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 1,500 shares during the last quarter. US Bancorp DE acquired a new stake in shares of Merus in the third quarter worth approximately $103,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 489 shares during the last quarter. Farallon Capital Management LLC acquired a new stake in shares of Merus in the second quarter worth approximately $237,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Merus in the second quarter worth approximately $242,000. 96.14% of the stock is owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.